Consumer Driven Health Care

Sens. Tim Kaine and Mark R. Warner, who both have championed to lower the cost of prescription drugs, applauded Sanofi, Novo Nordisk and Eli Lilly – the three major insulin manufacturers – for slashing prices, effective Jan. 1, 2024.

Due to a nationwide shortage of therapists, about a third of U.S. employers say they offer employees AI-based wellness and mental health programs, yet researchers say there isn't enough evidence that the programs work.

The Food and Drug Administration approved 55 new treatments in 2023, representing a nearly 50% increase from the year before, with Pfizer gaining the highest number of high-profile approvals covering a wide range of illnesses.

Health and retirement benefits are more important now than they've ever been as employers compete for top talent, with employees' mental health now taking a more prominent place in a company's benefits package.

Despite the Biden administration's numerous initiatives to crack down on the high cost of drugs, several big drugmakers will hike prices this month, with Pfizer announcing over a quarter of the increases.

After the Federal Trade Commission sent warning letters to 10 drugmakers over 100 "improper" patents, 3 chose to delist their patents from the FDA's registry, potentially accelerating the approval of generic versions.

One of the nation's largest health insurance providers was using the same AI tool, nH Predict – with an alleged 90% error rate that overrides medical judgment – that UnitedHealthcare was sued for in November.

Osterhaus Pharmacy in Iowa filed a class action lawsuit against UnitedHealth's pharmacy benefit manager Optum Rx, alleging it forces pharmacies to agree to retroactive fees that can cause pharmacies to dispense drugs at a loss.